Patients with psoriasis show a durable clinical response to the anti-IL-23 biologic, risankizumab, even after treatment cessation. Here, Jiang et al. generate a longitudinal single-cell and spatial transcriptomics atlas of patients pre- and post-treatment. They reveal reduced CD8+ tissue-resident memory T cell expansion, diminished inflammatory dendritic cells, and decreased APOE+/IL34+ fibroblasts associated with lasting amelioration of psoriatic inflammation.
